Tag: neuromodulation therapy
Magnus announces first treatments in OLO clinical trial of novel depression...
Magnus Medical has announced that the first participants have been treated in the Open Label Optimisation (OLO) clinical trial evaluating the effectiveness of the...
Interim analysis of MOOD trial produces positive neuromodulation data in depression...
Neurolief has announced positive results from a planned interim analysis of the ongoing, randomised controlled MOOD pivotal trial, which is studying Relivion DP—a novel...
Education and collaboration key to continued advancement of painful diabetic neuropathy...
The neuromodulation space has proliferated significantly over the past few years, and one area in which this is most notable is with the expansion...
Flexible nanoelectrodes can “pave the way” for higher-resolution stimulation devices
Engineers at Rice University (Houston, USA) have created nanoelectrodes that are minimally invasive and exceptionally flexible—and, as such, have the potential to function as...
Saluda, Neuromod, Neuvotion secure funding rounds to boost neuromodulation technologies
This week, three companies developing novel neuromodulation technologies for use in the treatment of various neurological disorders have each separately announced the receipt of...
Barostim neuromodulation device misses primary endpoint in BEAT-HF trial
CVRx has announced the preliminary topline results of the BEAT-HF (Baroreflex activation therapy for heart failure) postmarket clinical trial.
The BEAT-HF postmarket phase of the...
Spinal cord stimulation and other modalities will benefit from greater understanding...
Despite their clear significance in pain management, gender differences relating to the ways patients respond to neuromodulation therapies are relatively poorly understood and underpinned...
Eight winners advance to Phase 2 in Neuromod Prize competition
Eight winners have been exclusively invited to join Phase 2 of the Neuromod Prize, a US$9.8 million competition to accelerate the development of targeted...
CVRx launches new version of neuromodulation device intended to treat heart...
CVRx—the developer of the “world’s first” US Food and Drug Administration (FDA)-approved neuromodulation device to treat the symptoms of heart failure—has launched its new...
Phase one winners announced in US$9.8 million Neuromod Prize competition
The National Institutes of Health (NIH) Common Fund has named eight winners of the first phase of the Neuromod Prize—a US$9.8 million competition to accelerate...
Abbott introduces Canada’s first remote neuromodulation patient-care technology
Abbott recently announced the Health Canada licensing of NeuroSphere virtual clinic, a remote programming technology that the company claims is the first of its kind...
PathMaker initiates US multicentre trial evaluating non-invasive post-stroke spasticity treatment
PathMaker Neurosystems has announced initiation of its US multicentre clinical trial to evaluate MyoRegulator for the non-invasive treatment of post-stroke upper-limb spasticity. The trial is...
AI, cost reductions and more represent bright future for neuromodulation industry
On technological and commercial fronts alike, the neuromodulation space is one of the more rapidly evolving subsectors within the medical industry—and has undergone a...
Researchers pave way for adaptive DBS treatment after identifying OCD-associated brain...
In an effort to improve treatment for obsessive-compulsive disorder (OCD), a team of researchers has—for the first time, according to a Brown University (Providence,...
Salim Hayek
Salim Hayek is chief of the Division of Pain Medicine at University Hospitals of Cleveland and a professor in Case Western Reserve University’s Department...
NIH launches first phase of US$9.8 million competition to accelerate development...
The National Institutes of Health (NIH) has launched the first phase of the Neuromod Prize—a US$9.8 million competition to accelerate the development of neuromodulation therapies....
NANS 2022: Telehealth to play key role in improving patient access...
COVID-19 may have held a defining role in the “rebirth” of telehealth and remote care models in the USA, but their utility in improving...
Novel neuromodulation technique could be “gamechanger” in treatment-resistant depression
Stanford accelerated intelligent neuromodulation therapy (SAINT)—a novel, high-dose intermittent theta-burst stimulation (iTBS)—was found to be safe and more effective than sham stimulation in a...
